Compile Data Set for Download or QSAR
Report error Found 488 Enz. Inhib. hit(s) with all data for entry = 11907
TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659277(8-cyclopentyl-N-(1- (methylsulfonyl)piperidin- 4-y...)
Affinity DataIC50: 200nMAssay Description:The luminescent signal generated is proportional to the ADP concentration produced and is correlated with the kinase activity. CDK1/Cyclin B1 was pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659277(8-cyclopentyl-N-(1- (methylsulfonyl)piperidin- 4-y...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659277(8-cyclopentyl-N-(1- (methylsulfonyl)piperidin- 4-y...)
Affinity DataIC50: 200nMAssay Description:CDK4/Cyclin D1 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide 5-FAM-Dyrktide (5-FAM-RRRFR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659277(8-cyclopentyl-N-(1- (methylsulfonyl)piperidin- 4-y...)
Affinity DataIC50: 200nMAssay Description:In a CHEF assay, phosphorylation of a peptide substrate results in proportional increase in fluorescence. CHEF kinase assay use peptide substrates co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659283(N-(1-(methylsulfonyl)piperidin-4-yl)-8-(pyrrolidin...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659283(N-(1-(methylsulfonyl)piperidin-4-yl)-8-(pyrrolidin...)
Affinity DataIC50: 200nMAssay Description:CDK4/Cyclin D1 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide 5-FAM-Dyrktide (5-FAM-RRRFR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659283(N-(1-(methylsulfonyl)piperidin-4-yl)-8-(pyrrolidin...)
Affinity DataIC50: 200nMAssay Description:In a CHEF assay, phosphorylation of a peptide substrate results in proportional increase in fluorescence. CHEF kinase assay use peptide substrates co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659284(8-(2,2-difluoro-6-azaspiro[3.4]octan-6-yl)-N-(1-(m...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659284(8-(2,2-difluoro-6-azaspiro[3.4]octan-6-yl)-N-(1-(m...)
Affinity DataIC50: 200nMAssay Description:CDK4/Cyclin D1 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide 5-FAM-Dyrktide (5-FAM-RRRFR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659284(8-(2,2-difluoro-6-azaspiro[3.4]octan-6-yl)-N-(1-(m...)
Affinity DataIC50: 200nMAssay Description:In a CHEF assay, phosphorylation of a peptide substrate results in proportional increase in fluorescence. CHEF kinase assay use peptide substrates co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659289(6-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)quin...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659289(6-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)quin...)
Affinity DataIC50: 200nMAssay Description:CDK4/Cyclin D1 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide 5-FAM-Dyrktide (5-FAM-RRRFR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659289(6-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)quin...)
Affinity DataIC50: 200nMAssay Description:In a CHEF assay, phosphorylation of a peptide substrate results in proportional increase in fluorescence. CHEF kinase assay use peptide substrates co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659303(1-(7-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)q...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659303(1-(7-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)q...)
Affinity DataIC50: 200nMAssay Description:CDK4/Cyclin D1 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide 5-FAM-Dyrktide (5-FAM-RRRFR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659303(1-(7-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)q...)
Affinity DataIC50: 200nMAssay Description:In a CHEF assay, phosphorylation of a peptide substrate results in proportional increase in fluorescence. CHEF kinase assay use peptide substrates co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659309(N-(1-(methylsulfonyl)piperidin-4-yl)-8-(2-oxa-7-az...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659312((1-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)qui...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659312((1-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)qui...)
Affinity DataIC50: 200nMAssay Description:CDK4/Cyclin D1 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide 5-FAM-Dyrktide (5-FAM-RRRFR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659312((1-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)qui...)
Affinity DataIC50: 200nMAssay Description:In a CHEF assay, phosphorylation of a peptide substrate results in proportional increase in fluorescence. CHEF kinase assay use peptide substrates co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659316(8-(4-cyclopropylpiperazin-1-yl)-N-(1-(methylsulfon...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659318(2-(1-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)q...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659318(2-(1-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)q...)
Affinity DataIC50: 200nMAssay Description:CDK4/Cyclin D1 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide 5-FAM-Dyrktide (5-FAM-RRRFR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659318(2-(1-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)q...)
Affinity DataIC50: 200nMAssay Description:In a CHEF assay, phosphorylation of a peptide substrate results in proportional increase in fluorescence. CHEF kinase assay use peptide substrates co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659319(N-(1-(methylsulfonyl)piperidin-4-yl)-8-(2,6-diazas...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659319(N-(1-(methylsulfonyl)piperidin-4-yl)-8-(2,6-diazas...)
Affinity DataIC50: 200nMAssay Description:CDK4/Cyclin D1 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide 5-FAM-Dyrktide (5-FAM-RRRFR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659320(8-(1-cyclopropyl-7-oxa-2- azaspiro[3.5]nonan-2-yl)...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659321(8-(4-(cyclopropylmethyl)piperazin-1-yl)-N-(1-(meth...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase/G2/mitotic-specific cyclin- 1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659322(2-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)quin...)
Affinity DataIC50: 200nMAssay Description:The luminescent signal generated is proportional to the ADP concentration produced and is correlated with the kinase activity. CDK1/Cyclin B1 was pur...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659322(2-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)quin...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659322(2-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)quin...)
Affinity DataIC50: 200nMAssay Description:CDK4/Cyclin D1 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide 5-FAM-Dyrktide (5-FAM-RRRFR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659322(2-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)quin...)
Affinity DataIC50: 200nMAssay Description:In a CHEF assay, phosphorylation of a peptide substrate results in proportional increase in fluorescence. CHEF kinase assay use peptide substrates co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659323(6-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)quin...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659323(6-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)quin...)
Affinity DataIC50: 200nMAssay Description:CDK4/Cyclin D1 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide 5-FAM-Dyrktide (5-FAM-RRRFR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659323(6-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)quin...)
Affinity DataIC50: 200nMAssay Description:In a CHEF assay, phosphorylation of a peptide substrate results in proportional increase in fluorescence. CHEF kinase assay use peptide substrates co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659324(8-(4- (diethylamino)piperidin-1- yl)-N-(1- (methyl...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659326(N-(1-(methylsulfonyl)piperidin-4-yl)-8-(2-oxa-6-az...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659326(N-(1-(methylsulfonyl)piperidin-4-yl)-8-(2-oxa-6-az...)
Affinity DataIC50: 200nMAssay Description:CDK4/Cyclin D1 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide 5-FAM-Dyrktide (5-FAM-RRRFR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659326(N-(1-(methylsulfonyl)piperidin-4-yl)-8-(2-oxa-6-az...)
Affinity DataIC50: 200nMAssay Description:In a CHEF assay, phosphorylation of a peptide substrate results in proportional increase in fluorescence. CHEF kinase assay use peptide substrates co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659327(8-(7-(methylsulfonyl)-2,7- diazaspiro[4.4]nonan-2-...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659327(8-(7-(methylsulfonyl)-2,7- diazaspiro[4.4]nonan-2-...)
Affinity DataIC50: 200nMAssay Description:CDK4/Cyclin D1 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide 5-FAM-Dyrktide (5-FAM-RRRFR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659327(8-(7-(methylsulfonyl)-2,7- diazaspiro[4.4]nonan-2-...)
Affinity DataIC50: 200nMAssay Description:In a CHEF assay, phosphorylation of a peptide substrate results in proportional increase in fluorescence. CHEF kinase assay use peptide substrates co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659328(8-(2-methyl-2,6-diazaspiro[3.4]octan-6-yl)-N-(1-(m...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659328(8-(2-methyl-2,6-diazaspiro[3.4]octan-6-yl)-N-(1-(m...)
Affinity DataIC50: 200nMAssay Description:CDK4/Cyclin D1 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide 5-FAM-Dyrktide (5-FAM-RRRFR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659328(8-(2-methyl-2,6-diazaspiro[3.4]octan-6-yl)-N-(1-(m...)
Affinity DataIC50: 200nMAssay Description:In a CHEF assay, phosphorylation of a peptide substrate results in proportional increase in fluorescence. CHEF kinase assay use peptide substrates co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659329(1-(2-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)q...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659329(1-(2-(2-((1-(methylsulfonyl)piperidin-4-yl)amino)q...)
Affinity DataIC50: 200nMAssay Description:CDK4/Cyclin D1 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide 5-FAM-Dyrktide (5-FAM-RRRFR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 2/G1/S-specific cyclin-E1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659330(N-(1- (methylsulfonyl)piperidin- 4-yl)-8-(8-oxa-2-...)
Affinity DataIC50: 200nMAssay Description:ADP-Glo is performed in 2 steps upon completion of kinase reaction: a combined termination of kinase reaction and depletion of remaining ATP in the f...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659330(N-(1- (methylsulfonyl)piperidin- 4-yl)-8-(8-oxa-2-...)
Affinity DataIC50: 200nMAssay Description:CDK4/Cyclin D1 catalyzes the production of ADP from ATP that accompanies the phosphoryl transfer to the substrate peptide 5-FAM-Dyrktide (5-FAM-RRRFR...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

TargetCyclin-dependent kinase 4/G1/S-specific cyclin-D1(Human)
Iambic Therapeutics

US Patent
LigandPNGBDBM659330(N-(1- (methylsulfonyl)piperidin- 4-yl)-8-(8-oxa-2-...)
Affinity DataIC50: 200nMAssay Description:In a CHEF assay, phosphorylation of a peptide substrate results in proportional increase in fluorescence. CHEF kinase assay use peptide substrates co...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/4/2024
Entry Details
Go to US Patent

Displayed 1 to 50 (of 488 total ) | Next | Last >>
Jump to: